Mahalingasivam Viyaasan, Faucon Anne-Laure, Sjölander Arvid, Bosi Alessandro, González-Ortiz Ailema, Lando Stefania, Fu Edouard L, Nitsch Dorothea, Bruchfeld Annette, Evans Marie, Wing Kevin, Mansfield Kathryn E, Tomlinson Laurie, Carrero Juan-Jesús
Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
JAMA Netw Open. 2024 Dec 2;7(12):e2450014. doi: 10.1001/jamanetworkopen.2024.50014.
COVID-19 infection has been associated with acute kidney injury. However, its possible association with long-term kidney function is not well understood.
To investigate whether kidney function decline accelerated after COVID-19 compared with after other respiratory tract infections.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used linked data from the Stockholm Creatinine Measurements (SCREAM) Project between February 1, 2018, and January 1, 2022, in Stockholm, Sweden. All hospitalized and nonhospitalized adults in the database with at least 1 estimated glomerular filtration rate (eGFR) measurement in the 2 years prior to a COVID-19 positive test result or pneumonia diagnosis were selected. Statistical analyses were conducted between June 2023 and October 2024.
COVID-19 and pneumonia (including influenza).
Mean annual change in eGFR after COVID-19 and after pneumonia was calculated with a linear regression model.
The COVID-19 cohort comprised 134 565 individuals (74 819 females [55.6%]; median [IQR] age, 51 [37-64] years). The pneumonia cohort consisted of 35 987 individuals (19 359 females [53.8%]; median [IQR] age, 71 [56-81] years). The median (IQR) baseline eGFR was 94 (79-107) mL/min/1.73m2 for the COVID-19 cohort and 79 (61-92) mL/min/1.73m2 for the pneumonia cohort. After adjustment for covariates, both infections demonstrated accelerated annual eGFR decline, with greater magnitude of decline after COVID-19 (3.4% [95% CI, 3.2%-3.5%] after COVID-19; 2.3% [95% CI, 2.1%-2.5%] after pneumonia). This decline was more severe among individuals hospitalized for COVID-19 (5.4%; 95% CI, 5.2%-5.6%) but remained similar among those hospitalized for pneumonia.
This cohort study found an association between COVID-19 and accelerated decline in kidney function, particularly after hospitalization, compared with pneumonia. People who were hospitalized for COVID-19 should receive closer monitoring of kidney function to ensure early diagnosis and optimized management of chronic kidney disease to effectively prevent complications and further decline.
新型冠状病毒肺炎(COVID-19)感染与急性肾损伤有关。然而,其与长期肾功能的可能关联尚不清楚。
研究与其他呼吸道感染后相比,COVID-19后肾功能下降是否加速。
设计、设置和参与者:这项队列研究使用了瑞典斯德哥尔摩2018年2月1日至2022年1月1日期间斯德哥尔摩肌酐测量(SCREAM)项目的关联数据。选择数据库中在COVID-19检测呈阳性或肺炎诊断前2年内至少有1次估算肾小球滤过率(eGFR)测量值的所有住院和非住院成年人。2023年6月至2024年10月进行统计分析。
COVID-19和肺炎(包括流感)。
采用线性回归模型计算COVID-19后和肺炎后eGFR的年均变化。
COVID-19队列包括134565人(74819名女性[55.6%];年龄中位数[四分位间距],51[37-64]岁)。肺炎队列由35987人组成(19359名女性[53.8%];年龄中位数[四分位间距],71[56-81]岁)。COVID-19队列的基线eGFR中位数(四分位间距)为94(79-107)mL/(min·1.73m²),肺炎队列的基线eGFR中位数(四分位间距)为79(61-92)mL/(min·1.73m²)。在对协变量进行调整后,两种感染均显示eGFR年度下降加速,COVID-19后的下降幅度更大(COVID-19后为3.4%[95%CI,3.2%-3.5%];肺炎后为2.3%[95%CI,2.1%-2.5%])。这种下降在因COVID-19住院的个体中更为严重(5.4%;95%CI,5.2%-5.6%),但在因肺炎住院的个体中仍然相似。
这项队列研究发现,与肺炎相比,COVID-19与肾功能加速下降有关,尤其是在住院后。因COVID-19住院的患者应接受更密切的肾功能监测,以确保慢性肾脏病的早期诊断和优化管理,从而有效预防并发症和进一步恶化。